MetaADEDB 2.0 @ LMMD
Sitagliptin Phosphate
(IQFYVLUXQXSJJN-SBSPUUFOSA-N)
Structure
SMILES
OP(=O)(O)O.N[C@H](Cc1cc(F)c(cc1F)F)CC(=O)N1CCn2c(C1)nnc2C(F)(F)F
Molecular Formula:
C16H18F6N5O5P
Molecular Weight:
505.309
Log P:
1.7261
Hydrogen Bond Acceptor:
10
Hydrogen Bond Donor:
4
TPSA:
164.61
CAS Number(s):
654671-78-0; 847445-79-8
Synonym(s)
1.
Sitagliptin Phosphate
2.
4-Oxo-4-(3-(trifluoromethyl)-5,6-dihydro(1,2,4)triazolo(4,3-a)pyrazin-7(8H)-yl)-1-(2,4,5-trifluorophenyl)butan-2-amine
3.
Januvia
4.
MK 0431
5.
MK-0431
6.
MK0431
7.
Sitagliptin
8.
Sitagliptin Monophosphate Monohydrate
9.
Sitagliptin Phosphate Anhydrous
10.
Sitagliptin Phosphate Monohydrate
11.
0431, MK
12.
Anhydrous, Sitagliptin Phosphate
13.
Monohydrate, Sitagliptin Monophosphate
14.
Monohydrate, Sitagliptin Phosphate
15.
Monophosphate Monohydrate, Sitagliptin
16.
Phosphate Anhydrous, Sitagliptin
17.
Phosphate Monohydrate, Sitagliptin
18.
Phosphate, Sitagliptin
External Link(s)
MeSHD000068900
PubChem Compound6451150
139241319
BindingDB50206822
CHEMBLCHEMBL393336
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Pancreatic carcinomaFAERS: 12
Canada Vigilance: 1		Canada Vigilance
US FAERS
2Diabetes mellitus inadequate controlFAERS: 10US FAERS
3Lipase increasedFAERS: 7US FAERS
4RhabdomyolysisFAERS: 5US FAERS
5AngioedemaFAERS: 4US FAERS
6DizzinessFAERS: 4US FAERS
7Drug ineffectiveFAERS: 4US FAERS
8Abdominal PainFAERS: 3
Canada Vigilance: 1		Canada Vigilance
US FAERS
9AstheniaFAERS: 3US FAERS
10Blood creatine phosphokinase increasedFAERS: 3US FAERS
11Chest PainFAERS: 3US FAERS
12FatigueFAERS: 3US FAERS
13Myocardial InfarctionFAERS: 3US FAERS
14No adverse eventFAERS: 3US FAERS
15PancreatitisFAERS: 3
Canada Vigilance: 1		Canada Vigilance
US FAERS
16PemphigusFAERS: 3US FAERS
17Seronegative arthritisFAERS: 3US FAERS
18Skin lesionFAERS: 3US FAERS
19VomitingFAERS: 3US FAERS
20Accidental exposure to productFAERS: 2US FAERS
21Adverse eventFAERS: 2
Canada Vigilance: 1		Canada Vigilance
US FAERS
22Blood glucose abnormalFAERS: 2US FAERS
23Blood glucose increasedFAERS: 2US FAERS
24Cerebral InfarctionFAERS: 2US FAERS
25Cerebrovascular accidentFAERS: 2US FAERS
26ChromaturiaFAERS: 2US FAERS
27Decreased vibratory senseFAERS: 2US FAERS
28DehydrationFAERS: 2US FAERS
29Drug prescribing errorFAERS: 2US FAERS
30HeadacheFAERS: 2US FAERS
31Intestinal ObstructionFAERS: 2US FAERS
32Lower respiratory tract infectionFAERS: 2US FAERS
33MyopathyFAERS: 2US FAERS
34OverdoseFAERS: 2US FAERS
35PolyarthritisFAERS: 2US FAERS
36Temperature perception test abnormalFAERS: 2US FAERS
37Wrong technique in product usage processFAERS: 2US FAERS
38Abdominal discomfortFAERS: 1US FAERS
39AgitationFAERS: 1US FAERS
40Alanine Aminotransferase IncreasedFAERS: 1US FAERS
41AlopeciaFAERS: 1US FAERS
42Amylase increasedFAERS: 1US FAERS
43Angina PectorisFAERS: 1US FAERS
44AphoniaFAERS: 1US FAERS
45Aspartate Aminotransferase IncreasedFAERS: 1US FAERS
46AsthmaFAERS: 1US FAERS
47Atrial FibrillationFAERS: 1US FAERS
48Autoimmune PancreatitisFAERS: 1US FAERS
49BedriddenFAERS: 1US FAERS
50Blood glucose decreasedFAERS: 1US FAERS
51Blood glucose fluctuationFAERS: 1US FAERS
52Brain ContusionFAERS: 1US FAERS
53BronchospasmFAERS: 1US FAERS
54Cerebral ThrombosisFAERS: 1US FAERS
55Chest discomfortFAERS: 1US FAERS
56CholangiocarcinomaFAERS: 1US FAERS
57CholelithiasisFAERS: 1US FAERS
58ConstipationFAERS: 1US FAERS
59DeliriumFAERS: 1US FAERS
60Diabetes MellitusFAERS: 1US FAERS
61DiplopiaFAERS: 1US FAERS
62Drug dispensing errorFAERS: 1US FAERS
63Drug dose omissionFAERS: 1US FAERS
64Drug effect incompleteFAERS: 1US FAERS
65ErythemaFAERS: 1US FAERS
66FolliculitisFAERS: 1US FAERS
67Gastrointestinal hypomotilityFAERS: 1US FAERS
68HemiplegiaFAERS: 1US FAERS
69Hepatic necrosisFAERS: 1US FAERS
70Hepatitis BFAERS: 1US FAERS
71HerniaFAERS: 1
Canada Vigilance: 1		Canada Vigilance
US FAERS
72Hypertensive crisisFAERS: 1US FAERS
73ImmobileFAERS: 1US FAERS
74Impaired gastric emptyingFAERS: 1US FAERS
75Inappropriate schedule of drug administrationFAERS: 1US FAERS
76Infective spondylitisFAERS: 1US FAERS
77InfluenzaFAERS: 1US FAERS
78Intentional drug misuseFAERS: 1US FAERS
79Lichen PlanusFAERS: 1US FAERS
80Memory impairmentFAERS: 1US FAERS
81MyalgiaFAERS: 1US FAERS
82NasopharyngitisFAERS: 1US FAERS
83NauseaFAERS: 1US FAERS
84NephrolithiasisFAERS: 1US FAERS
85NeutropeniaFAERS: 1US FAERS
86Oropharyngeal painFAERS: 1US FAERS
87OverweightFAERS: 1US FAERS
88Pancreatic enzymes increasedFAERS: 1US FAERS
89PeriarthritisFAERS: 1US FAERS
90Pneumatosis intestinalisFAERS: 1US FAERS
91PneumobiliaFAERS: 1US FAERS
92PneumoniaFAERS: 1US FAERS
93Poor quality sleepFAERS: 1US FAERS
94Prescription drug used without a prescriptionFAERS: 1US FAERS
95Product use issueFAERS: 1US FAERS
96PruritusFAERS: 1US FAERS
97Pulmonary EmbolismFAERS: 1US FAERS
98Pulmonary FibrosisFAERS: 1US FAERS
99Rheumatoid ArthritisFAERS: 1US FAERS
100Rheumatoid neutrophilic dermatosisFAERS: 1US FAERS
101Suicide attemptFAERS: 1US FAERS
102SwellingFAERS: 1US FAERS
103ThrombocytopeniaFAERS: 1US FAERS
104Weight decreasedFAERS: 1US FAERS
105Wrong drug administeredFAERS: 1US FAERS
106Edema24534256CTD
107Hyperglycemia23466488CTD
108Hypertrophy24534256CTD
109Inflammation22733167
24534256		CTD
110MalaiseCanada Vigilance: 1Canada Vigilance
111Necrosis24534256CTD
112Pancreatic Diseases24534256CTD
113Stevens-Johnson Syndrome25811541CTD
114Vascular Diseases24534256CTD
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120295

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.